Laliberte Kevin 4
4 · Dova Pharmaceuticals Inc. · Filed Oct 2, 2019
Insider Transaction Report
Form 4
Laliberte Kevin
Sr. VP, Product Development
Transactions
- Sale
Common Stock
2019-09-30$28.00/sh−3,100$86,800→ 5,357 total - Sale
Common Stock
2019-09-30$28.00/sh−596$16,688→ 4,761 total
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan based on a limit price order adopted by the Reporting Person.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person with the intent to cover withholding taxes in connection with the settlement of restricted stock units.